LMAT LeMaitre Vascular Inc

BURLINGTON, Mass., Nov. 16 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) today announced the commercial launch of the TT(TM) Tortuous Tracker Delivery System, the next-generation introducer for LeMaitre Vascular's EndoFit(R) and UniFit(TM) Aortic Stent Graft product lines. The new delivery system will be sold beginning on Monday, November 19th, in the European Union and other select markets outside of the United States. The TT system is designed to simplify stent graft implants by requiring reduced deployment force, providing the physician with increased control over placement of the stent graft in the aorta. The TT system offers better flexibility and an improved coating to increase maneuverability through blood vessels and a three-part valve system to minimize blood loss during the medical procedure. The TT system also provides better visualization during the procedure and a more ergonomic design. "The TT system should improve the ease of use and therefore the performance of our endovascular stent grafts," said Ryan Connelly, Director, Research & Development of LeMaitre Vascular. "Since we acquired our stent graft product lines in 2005, we have carefully studied what vascular surgeons need to successfully deliver and deploy aortic stent grafts. The new TT system gives them what they have been asking for, which will enable better clinical results and improve patients' lives." The TT system has already been used by physicians in over a dozen procedures designed to provide the company with pre-launch clinical feedback. "I was very pleased with the flexibility of the device and its ability to navigate tortuous vessels," said Thomas Larzon, MD, Director of the EndoVascular Unit at Orebro University Hospital in Sweden. "It took much less physical effort to deploy the stent graft, which meant that I could more precisely position the stent graft where it would provide the best outcome for the patient." "We are pleased to be able to offer a delivery system that we believe meets the high performance standards set by our stent graft products," said George W. LeMaitre, Chairman and CEO of LeMaitre Vascular. "We believe that the prior generation delivery system had discouraged adoption of our stent grafts. The TT system removes this impediment to growth." The TT system will initially be available in a limited range of sizes as the company scales its production, with all sizes expected to become available by the end of 2008. LeMaitre Vascular will be hosting its first ever Analyst Day at the Marriott Marquis Hotel in New York City, on Monday, November 19th. Management, along with vascular surgeon customers, will be giving an overview and update on the Company and its products, including the new TT Tortuous Tracker Delivery System. A live audio webcast of the presentation will be available via the Internet at http://www.lemaitre.com/investor and will be available for replay for 30 days. The TT Tortuous Tracker Delivery System and the EndoFit and UniFit Aortic Stent Grafts are not approved for sale in the United States. About LeMaitre Vascular LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803. Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the future clinical performance of the TT Tortuous Tracker Delivery System and the impact that the device may have on LeMaitre Vascular's growth. Although LeMaitre Vascular believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, these forward-looking statements are neither promises nor guarantees. LeMaitre Vascular's business is subject to significant risks and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: the risk that the TT Tortuous Tracker Delivery System fails to provide the desired safety and efficacy following the commercial launch or is not accepted by the market for other reasons; the risk that LeMaitre Vascular cannot adequately effectively manufacture all necessary sizes of the device or scale up production at reasonable costs; and other risk factors that are discussed in LeMaitre Vascular's Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. The forward-looking statements made in this release are made only as of the date hereof and LeMaitre Vascular disclaims any intention or responsibility for updating predictions or expectations contained in this release. DATASOURCE: LeMaitre Vascular, Inc. CONTACT: Aaron Grossman, Investor Relations of LeMaitre Vascular, Inc., +1-781-221-2266 Web site: http://www.lemaitre.com/

Copyright